Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEVERAGE: Venetoclax, Obinutuzumab, and Lenalidomide in Follicular Lymphoma
NCT03980171Phase 2Active, not recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Aug 2019
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of venetoclax in follicular lymphoma (FL), sponsored by Peter MacCallum Cancer Centre. Primary endpoints: Dose limiting toxicities, Recommended phase II dose and 10 more. Started Aug 2019; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03980171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03980171.